{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:47:24Z","timestamp":1793836044219,"version":"4.6.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ijcard.2024.132118","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:41:52Z","timestamp":1714498912000},"page":"132118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study"],"prefix":"10.1016","volume":"408","author":[{"given":"Paulus","family":"Kirchhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameet","family":"Bakhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"de Asmundis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Deharo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Lopez-de-Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Fronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Lamparter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Laeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Smolnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Waltenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.132118_bb0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14779072.2023.2160319","article-title":"Atrial fibrillation and stroke","volume":"21","author":"Choi","year":"2023","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.ijcard.2024.132118_bb0010","first-page":"880","article-title":"Atrial fibrillation in older patients-reducing stroke risk is not only about anticoagulation","volume":"13","author":"Win","year":"2016","journal-title":"J. Geriatr. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132118_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joim.12360","article-title":"Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation","volume":"278","author":"Shields","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ijcard.2024.132118_bb0020","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2024.132118_bb0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132118_bb0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2024.132118_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.132118_bb0040","series-title":"Lixiana: Summary of Product Characteristics","year":"2015"},{"key":"10.1016\/j.ijcard.2024.132118_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2459\/JCM.0000000000000737","article-title":"Design and rationale of the edoxaban treatment in routiNe clinical prActice for patients with atrial fibrillation in Europe (ETNA-AF-Europe) study","volume":"20","author":"De Caterina","year":"2019","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"10.1016\/j.ijcard.2024.132118_bb0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12872-019-1144-x","article-title":"Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)","volume":"19","author":"De Caterina","year":"2019","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ijcard.2024.132118_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/ehjcvp\/pvac042","article-title":"Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care","volume":"9","author":"Kirchhof","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.ijcard.2024.132118_bb0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2021.03.004","article-title":"5-year outcomes from rivaroxaban therapy in atrial fibrillation: results from the Dresden NOAC registry","volume":"202","author":"Tittl","year":"2021","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ijcard.2024.132118_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2019.08.012","article-title":"Safety and effectiveness of dabigatran at 2 years: final outcomes from phase II of the GLORIA-AF registry program","volume":"218","author":"Mazurek","year":"2019","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2024.132118_bb0070","first-page":"214","article-title":"GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation","volume":"8","author":"Fox","year":"2022","journal-title":"Eur Heart J-Qual Car."},{"key":"10.1016\/j.ijcard.2024.132118_bb0075","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132118_bb0080","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11739-020-02442-9","article-title":"Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF prolongation registry","volume":"16","author":"Renda","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.ijcard.2024.132118_bb0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a warfarin-treated population with atrial fibrillation","volume":"1","author":"Bjorck","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2024.132118_bb0090","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1160\/TH14-10-0859","article-title":"Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula","volume":"113","author":"Sjogren","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2024.132118_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0828-282X(07)70784-5","article-title":"The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study","volume":"23","author":"Parkash","year":"2007","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132118_bb0100","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/STROKEAHA.116.013343","article-title":"Anticoagulant-associated intracranial hemorrhage in the era of reversal agents","volume":"48","author":"Steiner","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2024.132118_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hest.2020.01.001","article-title":"Anticoagulant-associated intracerebral hemorrhage","volume":"1","author":"Morotti","year":"2020","journal-title":"Brain Hemorrhages"},{"key":"10.1016\/j.ijcard.2024.132118_bb0110","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1503\/cmaj.121218","article-title":"Rates of hemorrhage during warfarin therapy for atrial fibrillation","volume":"185","author":"Gomes","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.ijcard.2024.132118_bb0115","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New Engl J Med."},{"key":"10.1016\/j.ijcard.2024.132118_bb0120","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132118_bb0125","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132118_bb0130","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132118_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study","volume":"7","author":"de Groot","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.ijcard.2024.132118_bb0140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/fca-2021-0120","article-title":"Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis","volume":"18","author":"Deitelzweig","year":"2022","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132118_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.774109","article-title":"Efficacy and safety of non-recommended dose of new Oral anticoagulants in patients with atrial fibrillation: a systematic review and Meta-analysis","volume":"8","author":"Kong","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.ijcard.2024.132118_bb0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ehjcvp\/pvy041","article-title":"Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study","volume":"5","author":"Amarenco","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.ijcard.2024.132118_bb0155","article-title":"Real-world prevalence of direct Oral anticoagulant off-label doses in atrial fibrillation: an epidemiological Meta-analysis","volume":"12","author":"Shen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcard.2024.132118_bb0160","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist Oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132118_bb0165","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct Oral anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132118_bb0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MAJ.0000000000000349","article-title":"Physician\u2019s fear of anticoagulant therapy in nonvalvular atrial fibrillation","volume":"348","author":"Sen","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijcard.2024.132118_bb0175","article-title":"The importance of appropriate dosing of nonvitamin K antagonist Oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"5","author":"Beyer-Westendorf","year":"2021","journal-title":"TH Open."},{"key":"10.1016\/j.ijcard.2024.132118_bb0180","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/heartjnl-2022-321114","article-title":"Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"109","author":"Caso","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2024.132118_bb0185","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/bcp.15534","article-title":"Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"89","author":"van den Dries","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2024.132118_bb0190","first-page":"18721","article-title":"Characteristics of non-valvular atrial fibrillation patients who benefit most from anticoagulation treatment","volume":"8","author":"Xing","year":"2015","journal-title":"Int. J. Clin. Exp. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732400740X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732400740X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T19:01:51Z","timestamp":1716922911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752732400740X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":38,"alternative-id":["S016752732400740X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132118","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132118"}}